Bioventix Plc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bioventix Plc with three other
companies in this sector in the United Kingdom:
GW Pharmaceuticals PLC
sales of £8.24 million [US$11.77 million]
(£5.79 million [US$8.26 million]
of which 45%
was Diagnostics Segment), and
Tissue Regenix Group PLC
(£5.23 million [US$7.48 million]
During the year ended June of 2017, sales at
Bioventix Plc were £7.25 million (US$10.35 million).
increase of 31.3%
versus 2016, when the company's sales were £5.52 million.
This was the fifth consecutive year of sales increases at Bioventix Plc
(and since 2012, sales have increased a total of 204%).